Please Wait.....
Report
Huntington's Disease Treatment Market By Drug type (Approved drugs, Offlabel drugs), By Age (Below 50 years, Above 50 years), By Distribution channel (Hospital pharmacies, Drug store and retail pharmacies, Online pharmacies): Global Opportunity Analysis and Industry Forecast, 2021-2031
Market Report I 2022-09-01 I 301 Pages I Allied Market Research
Huntington's disease is a rare, genetic condition that results in progressive destruction of brain nerve cells. The rate at which symptoms appear can differ from person to person. For some people, motor skill changes come first, followed by depressive symptoms. Changes in mood and strange behavior are frequent early warning indicators. Functional capacities of a person are significantly impacted by Huntington's disease, which typically causes mobility, cognitive, and psychological issues. Medications are available to help manage symptoms of Huntington's disease. There is currently no authorized disease-modifying medication for patients with Huntington's disease.
Major factors that drive growth of the Huntington's disease treatment market is increase in prevalence population and rise in demand for advanced drug types for controlling symptoms associated with Huntington's. In addition, strong drug type pipeline is a key trend in the market, which is expected to fuel growth during the forecast period.
Significant surge in patient population is one of the leading factors in the market as rise in patient lead to increase in demand for drugs. For instance, according to a research paper published by BJM Journal, there is high prevalence of HD in the UK. Such high prevalence of HD requires more ingenuity and responsiveness in its care. Thus, such high number of cases are expected to boost the Huntington's disease treatment market growth.
In addition, surge in demand for advanced treatment such as gene therapy and stem cell therapy in the past decade drives the market growth. Furthermore, rise in R&D investments in drug discovery and development serves as an lucrative opportunity for the market growth. However, complications associated with drug development process expected to hamper the market growth.
The global Huntington's disease treatment market is segmented on the basis of drug type, age, distribution channel, and region. On the basis of drug type, the market is categorized into approved drugs and off-label drugs. The approved drug segment is further classified into tetrabenazine and deutetrabenazine. By age, the market is divided into below 50 years and above 50 years. By distribution channel, it is segmented into hospital pharmacies, drug store & retail pharmacies, and online pharmacies. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and Latin America, the Middle East, and Africa (LAMEA).
Major players profiled in the report are Annexon Biosciences, Bausch Health Companies Inc, Dr.Reddy's Laboratories Ltd, Eli Lilly And Company, Hikma Pharmaceuticals PLC, Lupin, Medesis pharma SA, Mitochon Pharmaceuticals, Neurocrine bioscience Inc., Novartis, PTC Therapeutics, Inc, SOM Biotech, Sun Pharmaceuticals, Teva Pharmaceuticals Industries Ltd., UniQure, and Vaccinex, Inc.
Key Benefits For Stakeholders
-This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the huntington's disease treatment market analysis from 2021 to 2031 to identify the prevailing huntington's disease treatment market opportunities.
-The market research is offered along with information related to key drivers, restraints, and opportunities.
-Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
-In-depth analysis of the huntington's disease treatment market segmentation assists to determine the prevailing market opportunities.
-Major countries in each region are mapped according to their revenue contribution to the global market.
-Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
-The report includes the analysis of the regional as well as global huntington's disease treatment market trends, key players, market segments, application areas, and market growth strategies.
Key Market Segments
By Drug type
- Approved drugs
- Type
- Tetrabenazine
- Deutetrabenazine
- Offlabel drugs
By Age
- Below 50 years
- Above 50 years
By Distribution channel
- Hospital pharmacies
- Drug store and retail pharmacies
- Online pharmacies
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest Of Europe
- Asia-Pacific
- Japan
- China
- India
- Australia
- South Korea
- Rest Of Asia-Pacific
- LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest Of LAMEA
- Key Market Players
- Prilenia Therapeutics
- som biotech
- Bausch Health Companies Inc.
- Teva Pharmaceutical Industries Ltd.
- Novartis AG
- Lupin
- UniQure
- Hikma Pharmaceuticals plc
- Annexon Biosciences
- Dr. Reddy's Laboratories Ltd.
- Neurocrine Biosciences
- PTC Therapeutics
- AOP Health
- Medesis Pharma SA
- Mitochon Pharmaceuticals
- Sun Pharmaceuticals Industries Ltd.
- Vaccinex, Inc
CHAPTER 1:INTRODUCTION
1.1.Report description
1.2.Key market segments
1.3.Key benefits to the stakeholders
1.4.Research Methodology
1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools and models
CHAPTER 2:EXECUTIVE SUMMARY
2.1.Key findings of the study
2.2.CXO Perspective
CHAPTER 3:MARKET OVERVIEW
3.1.Market definition and scope
3.2.Key findings
3.2.1.Top investment pockets
3.3.Porter's five forces analysis
3.4.Top player positioning
3.5.Market dynamics
3.5.1.Drivers
3.5.2.Restraints
3.5.3.Opportunities
3.6.COVID-19 Impact Analysis on the market
CHAPTER 4: HUNTINGTON'S DISEASE TREATMENT MARKET, BY DRUG TYPE
4.1 Overview
4.1.1 Market size and forecast
4.2 Approved drugs
4.2.1 Key market trends, growth factors and opportunities
4.2.2 Market size and forecast, by region
4.2.3 Market share analysis by country
4.2.4 Approved drugs Huntington's Disease Treatment Market by Type
4.2.4.1 Tetrabenazine Market size and forecast, by region
4.2.4.2 Deutetrabenazine Market size and forecast, by region
4.3 Offlabel drugs
4.3.1 Key market trends, growth factors and opportunities
4.3.2 Market size and forecast, by region
4.3.3 Market share analysis by country
CHAPTER 5: HUNTINGTON'S DISEASE TREATMENT MARKET, BY AGE
5.1 Overview
5.1.1 Market size and forecast
5.2 Below 50 years
5.2.1 Key market trends, growth factors and opportunities
5.2.2 Market size and forecast, by region
5.2.3 Market share analysis by country
5.3 Above 50 years
5.3.1 Key market trends, growth factors and opportunities
5.3.2 Market size and forecast, by region
5.3.3 Market share analysis by country
CHAPTER 6: HUNTINGTON'S DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL
6.1 Overview
6.1.1 Market size and forecast
6.2 Hospital pharmacies
6.2.1 Key market trends, growth factors and opportunities
6.2.2 Market size and forecast, by region
6.2.3 Market share analysis by country
6.3 Drug store and retail pharmacies
6.3.1 Key market trends, growth factors and opportunities
6.3.2 Market size and forecast, by region
6.3.3 Market share analysis by country
6.4 Online pharmacies
6.4.1 Key market trends, growth factors and opportunities
6.4.2 Market size and forecast, by region
6.4.3 Market share analysis by country
CHAPTER 7: HUNTINGTON'S DISEASE TREATMENT MARKET, BY REGION
7.1 Overview
7.1.1 Market size and forecast
7.2 North America
7.2.1 Key trends and opportunities
7.2.2 North America Market size and forecast, by Drug type
7.2.2.1 North America Approved drugs Huntington's Disease Treatment Market by Type
7.2.3 North America Market size and forecast, by Age
7.2.4 North America Market size and forecast, by Distribution channel
7.2.5 North America Market size and forecast, by country
7.2.5.1 U.S.
7.2.5.1.1 Key market trends, growth factors and opportunities
7.2.5.1.2 Market size and forecast, by Drug type
7.2.5.1.3 Market size and forecast, by Age
7.2.5.1.4 Market size and forecast, by Distribution channel
7.2.5.2 Canada
7.2.5.2.1 Key market trends, growth factors and opportunities
7.2.5.2.2 Market size and forecast, by Drug type
7.2.5.2.3 Market size and forecast, by Age
7.2.5.2.4 Market size and forecast, by Distribution channel
7.2.5.3 Mexico
7.2.5.3.1 Key market trends, growth factors and opportunities
7.2.5.3.2 Market size and forecast, by Drug type
7.2.5.3.3 Market size and forecast, by Age
7.2.5.3.4 Market size and forecast, by Distribution channel
7.3 Europe
7.3.1 Key trends and opportunities
7.3.2 Europe Market size and forecast, by Drug type
7.3.2.1 Europe Approved drugs Huntington's Disease Treatment Market by Type
7.3.3 Europe Market size and forecast, by Age
7.3.4 Europe Market size and forecast, by Distribution channel
7.3.5 Europe Market size and forecast, by country
7.3.5.1 Germany
7.3.5.1.1 Key market trends, growth factors and opportunities
7.3.5.1.2 Market size and forecast, by Drug type
7.3.5.1.3 Market size and forecast, by Age
7.3.5.1.4 Market size and forecast, by Distribution channel
7.3.5.2 France
7.3.5.2.1 Key market trends, growth factors and opportunities
7.3.5.2.2 Market size and forecast, by Drug type
7.3.5.2.3 Market size and forecast, by Age
7.3.5.2.4 Market size and forecast, by Distribution channel
7.3.5.3 UK
7.3.5.3.1 Key market trends, growth factors and opportunities
7.3.5.3.2 Market size and forecast, by Drug type
7.3.5.3.3 Market size and forecast, by Age
7.3.5.3.4 Market size and forecast, by Distribution channel
7.3.5.4 Italy
7.3.5.4.1 Key market trends, growth factors and opportunities
7.3.5.4.2 Market size and forecast, by Drug type
7.3.5.4.3 Market size and forecast, by Age
7.3.5.4.4 Market size and forecast, by Distribution channel
7.3.5.5 Spain
7.3.5.5.1 Key market trends, growth factors and opportunities
7.3.5.5.2 Market size and forecast, by Drug type
7.3.5.5.3 Market size and forecast, by Age
7.3.5.5.4 Market size and forecast, by Distribution channel
7.3.5.6 Rest of Europe
7.3.5.6.1 Key market trends, growth factors and opportunities
7.3.5.6.2 Market size and forecast, by Drug type
7.3.5.6.3 Market size and forecast, by Age
7.3.5.6.4 Market size and forecast, by Distribution channel
7.4 Asia-Pacific
7.4.1 Key trends and opportunities
7.4.2 Asia-Pacific Market size and forecast, by Drug type
7.4.2.1 Asia-Pacific Approved drugs Huntington's Disease Treatment Market by Type
7.4.3 Asia-Pacific Market size and forecast, by Age
7.4.4 Asia-Pacific Market size and forecast, by Distribution channel
7.4.5 Asia-Pacific Market size and forecast, by country
7.4.5.1 Japan
7.4.5.1.1 Key market trends, growth factors and opportunities
7.4.5.1.2 Market size and forecast, by Drug type
7.4.5.1.3 Market size and forecast, by Age
7.4.5.1.4 Market size and forecast, by Distribution channel
7.4.5.2 China
7.4.5.2.1 Key market trends, growth factors and opportunities
7.4.5.2.2 Market size and forecast, by Drug type
7.4.5.2.3 Market size and forecast, by Age
7.4.5.2.4 Market size and forecast, by Distribution channel
7.4.5.3 India
7.4.5.3.1 Key market trends, growth factors and opportunities
7.4.5.3.2 Market size and forecast, by Drug type
7.4.5.3.3 Market size and forecast, by Age
7.4.5.3.4 Market size and forecast, by Distribution channel
7.4.5.4 Australia
7.4.5.4.1 Key market trends, growth factors and opportunities
7.4.5.4.2 Market size and forecast, by Drug type
7.4.5.4.3 Market size and forecast, by Age
7.4.5.4.4 Market size and forecast, by Distribution channel
7.4.5.5 South Korea
7.4.5.5.1 Key market trends, growth factors and opportunities
7.4.5.5.2 Market size and forecast, by Drug type
7.4.5.5.3 Market size and forecast, by Age
7.4.5.5.4 Market size and forecast, by Distribution channel
7.4.5.6 Rest of Asia-Pacific
7.4.5.6.1 Key market trends, growth factors and opportunities
7.4.5.6.2 Market size and forecast, by Drug type
7.4.5.6.3 Market size and forecast, by Age
7.4.5.6.4 Market size and forecast, by Distribution channel
7.5 LAMEA
7.5.1 Key trends and opportunities
7.5.2 LAMEA Market size and forecast, by Drug type
7.5.2.1 LAMEA Approved drugs Huntington's Disease Treatment Market by Type
7.5.3 LAMEA Market size and forecast, by Age
7.5.4 LAMEA Market size and forecast, by Distribution channel
7.5.5 LAMEA Market size and forecast, by country
7.5.5.1 Brazil
7.5.5.1.1 Key market trends, growth factors and opportunities
7.5.5.1.2 Market size and forecast, by Drug type
7.5.5.1.3 Market size and forecast, by Age
7.5.5.1.4 Market size and forecast, by Distribution channel
7.5.5.2 Saudi Arabia
7.5.5.2.1 Key market trends, growth factors and opportunities
7.5.5.2.2 Market size and forecast, by Drug type
7.5.5.2.3 Market size and forecast, by Age
7.5.5.2.4 Market size and forecast, by Distribution channel
7.5.5.3 South Africa
7.5.5.3.1 Key market trends, growth factors and opportunities
7.5.5.3.2 Market size and forecast, by Drug type
7.5.5.3.3 Market size and forecast, by Age
7.5.5.3.4 Market size and forecast, by Distribution channel
7.5.5.4 Rest of LAMEA
7.5.5.4.1 Key market trends, growth factors and opportunities
7.5.5.4.2 Market size and forecast, by Drug type
7.5.5.4.3 Market size and forecast, by Age
7.5.5.4.4 Market size and forecast, by Distribution channel
CHAPTER 8: COMPANY LANDSCAPE
8.1. Introduction
8.2. Top winning strategies
8.3. Product Mapping of Top 10 Player
8.4. Competitive Dashboard
8.5. Competitive Heatmap
8.6. Key developments
CHAPTER 9: COMPANY PROFILES
9.1 Prilenia Therapeutics
9.1.1 Company overview
9.1.2 Company snapshot
9.1.3 Operating business segments
9.1.4 Product portfolio
9.1.5 Business performance
9.1.6 Key strategic moves and developments
9.2 som biotech
9.2.1 Company overview
9.2.2 Company snapshot
9.2.3 Operating business segments
9.2.4 Product portfolio
9.2.5 Business performance
9.2.6 Key strategic moves and developments
9.3 Bausch Health Companies Inc.
9.3.1 Company overview
9.3.2 Company snapshot
9.3.3 Operating business segments
9.3.4 Product portfolio
9.3.5 Business performance
9.3.6 Key strategic moves and developments
9.4 Teva Pharmaceutical Industries Ltd.
9.4.1 Company overview
9.4.2 Company snapshot
9.4.3 Operating business segments
9.4.4 Product portfolio
9.4.5 Business performance
9.4.6 Key strategic moves and developments
9.5 Novartis AG
9.5.1 Company overview
9.5.2 Company snapshot
9.5.3 Operating business segments
9.5.4 Product portfolio
9.5.5 Business performance
9.5.6 Key strategic moves and developments
9.6 Lupin
9.6.1 Company overview
9.6.2 Company snapshot
9.6.3 Operating business segments
9.6.4 Product portfolio
9.6.5 Business performance
9.6.6 Key strategic moves and developments
9.7 UniQure
9.7.1 Company overview
9.7.2 Company snapshot
9.7.3 Operating business segments
9.7.4 Product portfolio
9.7.5 Business performance
9.7.6 Key strategic moves and developments
9.8 Hikma Pharmaceuticals plc
9.8.1 Company overview
9.8.2 Company snapshot
9.8.3 Operating business segments
9.8.4 Product portfolio
9.8.5 Business performance
9.8.6 Key strategic moves and developments
9.9 Annexon Biosciences
9.9.1 Company overview
9.9.2 Company snapshot
9.9.3 Operating business segments
9.9.4 Product portfolio
9.9.5 Business performance
9.9.6 Key strategic moves and developments
9.10 Dr. Reddy's Laboratories Ltd.
9.10.1 Company overview
9.10.2 Company snapshot
9.10.3 Operating business segments
9.10.4 Product portfolio
9.10.5 Business performance
9.10.6 Key strategic moves and developments
9.11 Neurocrine Biosciences
9.11.1 Company overview
9.11.2 Company snapshot
9.11.3 Operating business segments
9.11.4 Product portfolio
9.11.5 Business performance
9.11.6 Key strategic moves and developments
9.12 PTC Therapeutics
9.12.1 Company overview
9.12.2 Company snapshot
9.12.3 Operating business segments
9.12.4 Product portfolio
9.12.5 Business performance
9.12.6 Key strategic moves and developments
9.13 AOP Health
9.13.1 Company overview
9.13.2 Company snapshot
9.13.3 Operating business segments
9.13.4 Product portfolio
9.13.5 Business performance
9.13.6 Key strategic moves and developments
9.14 Medesis Pharma SA
9.14.1 Company overview
9.14.2 Company snapshot
9.14.3 Operating business segments
9.14.4 Product portfolio
9.14.5 Business performance
9.14.6 Key strategic moves and developments
9.15 Mitochon Pharmaceuticals
9.15.1 Company overview
9.15.2 Company snapshot
9.15.3 Operating business segments
9.15.4 Product portfolio
9.15.5 Business performance
9.15.6 Key strategic moves and developments
9.16 Sun Pharmaceuticals Industries Ltd.
9.16.1 Company overview
9.16.2 Company snapshot
9.16.3 Operating business segments
9.16.4 Product portfolio
9.16.5 Business performance
9.16.6 Key strategic moves and developments
9.17 Vaccinex, Inc
9.17.1 Company overview
9.17.2 Company snapshot
9.17.3 Operating business segments
9.17.4 Product portfolio
9.17.5 Business performance
9.17.6 Key strategic moves and developments
LIST OF TABLES
TABLE 1. GLOBAL HUNTINGTON'S DISEASE TREATMENT MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 2. HUNTINGTON'S DISEASE TREATMENT MARKET, FOR APPROVED DRUGS, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 3. HUNTINGTON'S DISEASE TREATMENT MARKET, FOR APPROVED DRUGS, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
TABLE 4. GLOBAL APPROVED DRUGS HUNTINGTON'S DISEASE TREATMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 5. HUNTINGTON'S DISEASE TREATMENT MARKET, FOR TETRABENAZINE, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 6. HUNTINGTON'S DISEASE TREATMENT MARKET, FOR DEUTETRABENAZINE, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 7. HUNTINGTON'S DISEASE TREATMENT MARKET, FOR OFFLABEL DRUGS, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 8. HUNTINGTON'S DISEASE TREATMENT MARKET, FOR OFFLABEL DRUGS, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
TABLE 9. GLOBAL HUNTINGTON'S DISEASE TREATMENT MARKET, BY AGE, 2021-2031 (REVENUE, $MILLION)
TABLE 10. HUNTINGTON'S DISEASE TREATMENT MARKET, FOR BELOW 50 YEARS, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 11. HUNTINGTON'S DISEASE TREATMENT MARKET, FOR BELOW 50 YEARS, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
TABLE 12. HUNTINGTON'S DISEASE TREATMENT MARKET, FOR ABOVE 50 YEARS, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 13. HUNTINGTON'S DISEASE TREATMENT MARKET, FOR ABOVE 50 YEARS, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
TABLE 14. GLOBAL HUNTINGTON'S DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 15. HUNTINGTON'S DISEASE TREATMENT MARKET, FOR HOSPITAL PHARMACIES, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 16. HUNTINGTON'S DISEASE TREATMENT MARKET, FOR HOSPITAL PHARMACIES, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
TABLE 17. HUNTINGTON'S DISEASE TREATMENT MARKET, FOR DRUG STORE AND RETAIL PHARMACIES, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 18. HUNTINGTON'S DISEASE TREATMENT MARKET, FOR DRUG STORE AND RETAIL PHARMACIES, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
TABLE 19. HUNTINGTON'S DISEASE TREATMENT MARKET, FOR ONLINE PHARMACIES, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 20. HUNTINGTON'S DISEASE TREATMENT MARKET, FOR ONLINE PHARMACIES, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
TABLE 21. HUNTINGTON'S DISEASE TREATMENT MARKET, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 22. NORTH AMERICA HUNTINGTON'S DISEASE TREATMENT MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 23. NORTH AMERICA APPROVED DRUGS HUNTINGTON'S DISEASE TREATMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 24. NORTH AMERICA HUNTINGTON'S DISEASE TREATMENT MARKET, BY AGE, 2021-2031 (REVENUE, $MILLION)
TABLE 25. NORTH AMERICA HUNTINGTON'S DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 26. NORTH AMERICA HUNTINGTON'S DISEASE TREATMENT MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
TABLE 27. U.S. HUNTINGTON'S DISEASE TREATMENT MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 28. U.S. HUNTINGTON'S DISEASE TREATMENT MARKET, BY AGE, 2021-2031 (REVENUE, $MILLION)
TABLE 29. U.S. HUNTINGTON'S DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 30. CANADA HUNTINGTON'S DISEASE TREATMENT MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 31. CANADA HUNTINGTON'S DISEASE TREATMENT MARKET, BY AGE, 2021-2031 (REVENUE, $MILLION)
TABLE 32. CANADA HUNTINGTON'S DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 33. MEXICO HUNTINGTON'S DISEASE TREATMENT MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 34. MEXICO HUNTINGTON'S DISEASE TREATMENT MARKET, BY AGE, 2021-2031 (REVENUE, $MILLION)
TABLE 35. MEXICO HUNTINGTON'S DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 36. EUROPE HUNTINGTON'S DISEASE TREATMENT MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 37. EUROPE APPROVED DRUGS HUNTINGTON'S DISEASE TREATMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 38. EUROPE HUNTINGTON'S DISEASE TREATMENT MARKET, BY AGE, 2021-2031 (REVENUE, $MILLION)
TABLE 39. EUROPE HUNTINGTON'S DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 40. EUROPE HUNTINGTON'S DISEASE TREATMENT MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
TABLE 41. GERMANY HUNTINGTON'S DISEASE TREATMENT MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 42. GERMANY HUNTINGTON'S DISEASE TREATMENT MARKET, BY AGE, 2021-2031 (REVENUE, $MILLION)
TABLE 43. GERMANY HUNTINGTON'S DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 44. FRANCE HUNTINGTON'S DISEASE TREATMENT MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 45. FRANCE HUNTINGTON'S DISEASE TREATMENT MARKET, BY AGE, 2021-2031 (REVENUE, $MILLION)
TABLE 46. FRANCE HUNTINGTON'S DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 47. UK HUNTINGTON'S DISEASE TREATMENT MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 48. UK HUNTINGTON'S DISEASE TREATMENT MARKET, BY AGE, 2021-2031 (REVENUE, $MILLION)
TABLE 49. UK HUNTINGTON'S DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 50. ITALY HUNTINGTON'S DISEASE TREATMENT MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 51. ITALY HUNTINGTON'S DISEASE TREATMENT MARKET, BY AGE, 2021-2031 (REVENUE, $MILLION)
TABLE 52. ITALY HUNTINGTON'S DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 53. SPAIN HUNTINGTON'S DISEASE TREATMENT MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 54. SPAIN HUNTINGTON'S DISEASE TREATMENT MARKET, BY AGE, 2021-2031 (REVENUE, $MILLION)
TABLE 55. SPAIN HUNTINGTON'S DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 56. REST OF EUROPE HUNTINGTON'S DISEASE TREATMENT MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 57. REST OF EUROPE HUNTINGTON'S DISEASE TREATMENT MARKET, BY AGE, 2021-2031 (REVENUE, $MILLION)
TABLE 58. REST OF EUROPE HUNTINGTON'S DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 59. ASIA-PACIFIC HUNTINGTON'S DISEASE TREATMENT MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 60. ASIA-PACIFIC APPROVED DRUGS HUNTINGTON'S DISEASE TREATMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 61. ASIA-PACIFIC HUNTINGTON'S DISEASE TREATMENT MARKET, BY AGE, 2021-2031 (REVENUE, $MILLION)
TABLE 62. ASIA-PACIFIC HUNTINGTON'S DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 63. ASIA-PACIFIC HUNTINGTON'S DISEASE TREATMENT MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
TABLE 64. JAPAN HUNTINGTON'S DISEASE TREATMENT MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 65. JAPAN HUNTINGTON'S DISEASE TREATMENT MARKET, BY AGE, 2021-2031 (REVENUE, $MILLION)
TABLE 66. JAPAN HUNTINGTON'S DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 67. CHINA HUNTINGTON'S DISEASE TREATMENT MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 68. CHINA HUNTINGTON'S DISEASE TREATMENT MARKET, BY AGE, 2021-2031 (REVENUE, $MILLION)
TABLE 69. CHINA HUNTINGTON'S DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 70. INDIA HUNTINGTON'S DISEASE TREATMENT MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 71. INDIA HUNTINGTON'S DISEASE TREATMENT MARKET, BY AGE, 2021-2031 (REVENUE, $MILLION)
TABLE 72. INDIA HUNTINGTON'S DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 73. AUSTRALIA HUNTINGTON'S DISEASE TREATMENT MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 74. AUSTRALIA HUNTINGTON'S DISEASE TREATMENT MARKET, BY AGE, 2021-2031 (REVENUE, $MILLION)
TABLE 75. AUSTRALIA HUNTINGTON'S DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 76. SOUTH KOREA HUNTINGTON'S DISEASE TREATMENT MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 77. SOUTH KOREA HUNTINGTON'S DISEASE TREATMENT MARKET, BY AGE, 2021-2031 (REVENUE, $MILLION)
TABLE 78. SOUTH KOREA HUNTINGTON'S DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 79. REST OF ASIA-PACIFIC HUNTINGTON'S DISEASE TREATMENT MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 80. REST OF ASIA-PACIFIC HUNTINGTON'S DISEASE TREATMENT MARKET, BY AGE, 2021-2031 (REVENUE, $MILLION)
TABLE 81. REST OF ASIA-PACIFIC HUNTINGTON'S DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 82. LAMEA HUNTINGTON'S DISEASE TREATMENT MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 83. LAMEA APPROVED DRUGS HUNTINGTON'S DISEASE TREATMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 84. LAMEA HUNTINGTON'S DISEASE TREATMENT MARKET, BY AGE, 2021-2031 (REVENUE, $MILLION)
TABLE 85. LAMEA HUNTINGTON'S DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 86. LAMEA HUNTINGTON'S DISEASE TREATMENT MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
TABLE 87. BRAZIL HUNTINGTON'S DISEASE TREATMENT MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 88. BRAZIL HUNTINGTON'S DISEASE TREATMENT MARKET, BY AGE, 2021-2031 (REVENUE, $MILLION)
TABLE 89. BRAZIL HUNTINGTON'S DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 90. SAUDI ARABIA HUNTINGTON'S DISEASE TREATMENT MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 91. SAUDI ARABIA HUNTINGTON'S DISEASE TREATMENT MARKET, BY AGE, 2021-2031 (REVENUE, $MILLION)
TABLE 92. SAUDI ARABIA HUNTINGTON'S DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 93. SOUTH AFRICA HUNTINGTON'S DISEASE TREATMENT MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 94. SOUTH AFRICA HUNTINGTON'S DISEASE TREATMENT MARKET, BY AGE, 2021-2031 (REVENUE, $MILLION)
TABLE 95. SOUTH AFRICA HUNTINGTON'S DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 96. REST OF LAMEA HUNTINGTON'S DISEASE TREATMENT MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 97. REST OF LAMEA HUNTINGTON'S DISEASE TREATMENT MARKET, BY AGE, 2021-2031 (REVENUE, $MILLION)
TABLE 98. REST OF LAMEA HUNTINGTON'S DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 99.PRILENIA THERAPEUTICS: COMPANY SNAPSHOT
TABLE 100.PRILENIA THERAPEUTICS: OPERATING SEGMENTS
TABLE 101.PRILENIA THERAPEUTICS: PRODUCT PORTFOLIO
TABLE 102.PRILENIA THERAPEUTICS: NET SALES,
TABLE 103.PRILENIA THERAPEUTICS: KEY STRATERGIES
TABLE 104.SOM BIOTECH: COMPANY SNAPSHOT
TABLE 105.SOM BIOTECH: OPERATING SEGMENTS
TABLE 106.SOM BIOTECH: PRODUCT PORTFOLIO
TABLE 107.SOM BIOTECH: NET SALES,
TABLE 108.SOM BIOTECH: KEY STRATERGIES
TABLE 109.BAUSCH HEALTH COMPANIES INC.: COMPANY SNAPSHOT
TABLE 110.BAUSCH HEALTH COMPANIES INC.: OPERATING SEGMENTS
TABLE 111.BAUSCH HEALTH COMPANIES INC.: PRODUCT PORTFOLIO
TABLE 112.BAUSCH HEALTH COMPANIES INC.: NET SALES,
TABLE 113.BAUSCH HEALTH COMPANIES INC.: KEY STRATERGIES
TABLE 114.TEVA PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT
TABLE 115.TEVA PHARMACEUTICAL INDUSTRIES LTD.: OPERATING SEGMENTS
TABLE 116.TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT PORTFOLIO
TABLE 117.TEVA PHARMACEUTICAL INDUSTRIES LTD.: NET SALES,
TABLE 118.TEVA PHARMACEUTICAL INDUSTRIES LTD.: KEY STRATERGIES
TABLE 119.NOVARTIS AG: COMPANY SNAPSHOT
TABLE 120.NOVARTIS AG: OPERATING SEGMENTS
TABLE 121.NOVARTIS AG: PRODUCT PORTFOLIO
TABLE 122.NOVARTIS AG: NET SALES,
TABLE 123.NOVARTIS AG: KEY STRATERGIES
TABLE 124.LUPIN: COMPANY SNAPSHOT
TABLE 125.LUPIN: OPERATING SEGMENTS
TABLE 126.LUPIN: PRODUCT PORTFOLIO
TABLE 127.LUPIN: NET SALES,
TABLE 128.LUPIN: KEY STRATERGIES
TABLE 129.UNIQURE: COMPANY SNAPSHOT
TABLE 130.UNIQURE: OPERATING SEGMENTS
TABLE 131.UNIQURE: PRODUCT PORTFOLIO
TABLE 132.UNIQURE: NET SALES,
TABLE 133.UNIQURE: KEY STRATERGIES
TABLE 134.HIKMA PHARMACEUTICALS PLC: COMPANY SNAPSHOT
TABLE 135.HIKMA PHARMACEUTICALS PLC: OPERATING SEGMENTS
TABLE 136.HIKMA PHARMACEUTICALS PLC: PRODUCT PORTFOLIO
TABLE 137.HIKMA PHARMACEUTICALS PLC: NET SALES,
TABLE 138.HIKMA PHARMACEUTICALS PLC: KEY STRATERGIES
TABLE 139.ANNEXON BIOSCIENCES: COMPANY SNAPSHOT
TABLE 140.ANNEXON BIOSCIENCES: OPERATING SEGMENTS
TABLE 141.ANNEXON BIOSCIENCES: PRODUCT PORTFOLIO
TABLE 142.ANNEXON BIOSCIENCES: NET SALES,
TABLE 143.ANNEXON BIOSCIENCES: KEY STRATERGIES
TABLE 144.DR. REDDY'S LABORATORIES LTD.: COMPANY SNAPSHOT
TABLE 145.DR. REDDY'S LABORATORIES LTD.: OPERATING SEGMENTS
TABLE 146.DR. REDDY'S LABORATORIES LTD.: PRODUCT PORTFOLIO
TABLE 147.DR. REDDY'S LABORATORIES LTD.: NET SALES,
TABLE 148.DR. REDDY'S LABORATORIES LTD.: KEY STRATERGIES
TABLE 149.NEUROCRINE BIOSCIENCES: COMPANY SNAPSHOT
TABLE 150.NEUROCRINE BIOSCIENCES: OPERATING SEGMENTS
TABLE 151.NEUROCRINE BIOSCIENCES: PRODUCT PORTFOLIO
TABLE 152.NEUROCRINE BIOSCIENCES: NET SALES,
TABLE 153.NEUROCRINE BIOSCIENCES: KEY STRATERGIES
TABLE 154.PTC THERAPEUTICS: COMPANY SNAPSHOT
TABLE 155.PTC THERAPEUTICS: OPERATING SEGMENTS
TABLE 156.PTC THERAPEUTICS: PRODUCT PORTFOLIO
TABLE 157.PTC THERAPEUTICS: NET SALES,
TABLE 158.PTC THERAPEUTICS: KEY STRATERGIES
TABLE 159.AOP HEALTH: COMPANY SNAPSHOT
TABLE 160.AOP HEALTH: OPERATING SEGMENTS
TABLE 161.AOP HEALTH: PRODUCT PORTFOLIO
TABLE 162.AOP HEALTH: NET SALES,
TABLE 163.AOP HEALTH: KEY STRATERGIES
TABLE 164.MEDESIS PHARMA SA: COMPANY SNAPSHOT
TABLE 165.MEDESIS PHARMA SA: OPERATING SEGMENTS
TABLE 166.MEDESIS PHARMA SA: PRODUCT PORTFOLIO
TABLE 167.MEDESIS PHARMA SA: NET SALES,
TABLE 168.MEDESIS PHARMA SA: KEY STRATERGIES
TABLE 169.MITOCHON PHARMACEUTICALS: COMPANY SNAPSHOT
TABLE 170.MITOCHON PHARMACEUTICALS: OPERATING SEGMENTS
TABLE 171.MITOCHON PHARMACEUTICALS: PRODUCT PORTFOLIO
TABLE 172.MITOCHON PHARMACEUTICALS: NET SALES,
TABLE 173.MITOCHON PHARMACEUTICALS: KEY STRATERGIES
TABLE 174.SUN PHARMACEUTICALS INDUSTRIES LTD.: COMPANY SNAPSHOT
TABLE 175.SUN PHARMACEUTICALS INDUSTRIES LTD.: OPERATING SEGMENTS
TABLE 176.SUN PHARMACEUTICALS INDUSTRIES LTD.: PRODUCT PORTFOLIO
TABLE 177.SUN PHARMACEUTICALS INDUSTRIES LTD.: NET SALES,
TABLE 178.SUN PHARMACEUTICALS INDUSTRIES LTD.: KEY STRATERGIES
TABLE 179.VACCINEX, INC: COMPANY SNAPSHOT
TABLE 180.VACCINEX, INC: OPERATING SEGMENTS
TABLE 181.VACCINEX, INC: PRODUCT PORTFOLIO
TABLE 182.VACCINEX, INC: NET SALES,
TABLE 183.VACCINEX, INC: KEY STRATERGIES
LIST OF FIGURES
FIGURE 1.HUNTINGTON'S DISEASE TREATMENT MARKET SEGMENTATION
FIGURE 2.HUNTINGTON'S DISEASE TREATMENT MARKET,2021-2031
FIGURE 3.HUNTINGTON'S DISEASE TREATMENT MARKET,2021-2031
FIGURE 4. TOP INVESTMENT POCKETS, BY REGION
FIGURE 5.PORTER FIVE-1
FIGURE 6.PORTER FIVE-2
FIGURE 7.PORTER FIVE-3
FIGURE 8.PORTER FIVE-4
FIGURE 9.PORTER FIVE-5
FIGURE 10.TOP PLAYER POSITIONING
FIGURE 11.HUNTINGTON'S DISEASE TREATMENT MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
FIGURE 12.HUNTINGTON'S DISEASE TREATMENT MARKET,BY DRUG TYPE,2021(%)
FIGURE 13.COMPARATIVE SHARE ANALYSIS OF APPROVED DRUGS HUNTINGTON'S DISEASE TREATMENT MARKET,2021-2031(%)
FIGURE 14.COMPARATIVE SHARE ANALYSIS OF OFFLABEL DRUGS HUNTINGTON'S DISEASE TREATMENT MARKET,2021-2031(%)
FIGURE 15.HUNTINGTON'S DISEASE TREATMENT MARKET,BY AGE,2021(%)
FIGURE 16.COMPARATIVE SHARE ANALYSIS OF BELOW 50 YEARS HUNTINGTON'S DISEASE TREATMENT MARKET,2021-2031(%)
FIGURE 17.COMPARATIVE SHARE ANALYSIS OF ABOVE 50 YEARS HUNTINGTON'S DISEASE TREATMENT MARKET,2021-2031(%)
FIGURE 18.HUNTINGTON'S DISEASE TREATMENT MARKET,BY DISTRIBUTION CHANNEL,2021(%)
FIGURE 19.COMPARATIVE SHARE ANALYSIS OF HOSPITAL PHARMACIES HUNTINGTON'S DISEASE TREATMENT MARKET,2021-2031(%)
FIGURE 20.COMPARATIVE SHARE ANALYSIS OF DRUG STORE AND RETAIL PHARMACIES HUNTINGTON'S DISEASE TREATMENT MARKET,2021-2031(%)
FIGURE 21.COMPARATIVE SHARE ANALYSIS OF ONLINE PHARMACIES HUNTINGTON'S DISEASE TREATMENT MARKET,2021-2031(%)
FIGURE 22.HUNTINGTON'S DISEASE TREATMENT MARKET BY REGION,2021
FIGURE 23.U.S. HUNTINGTON'S DISEASE TREATMENT MARKET,2021-2031($MILLION)
FIGURE 24.CANADA HUNTINGTON'S DISEASE TREATMENT MARKET,2021-2031($MILLION)
FIGURE 25.MEXICO HUNTINGTON'S DISEASE TREATMENT MARKET,2021-2031($MILLION)
FIGURE 26.GERMANY HUNTINGTON'S DISEASE TREATMENT MARKET,2021-2031($MILLION)
FIGURE 27.FRANCE HUNTINGTON'S DISEASE TREATMENT MARKET,2021-2031($MILLION)
FIGURE 28.UK HUNTINGTON'S DISEASE TREATMENT MARKET,2021-2031($MILLION)
FIGURE 29.ITALY HUNTINGTON'S DISEASE TREATMENT MARKET,2021-2031($MILLION)
FIGURE 30.SPAIN HUNTINGTON'S DISEASE TREATMENT MARKET,2021-2031($MILLION)
FIGURE 31.REST OF EUROPE HUNTINGTON'S DISEASE TREATMENT MARKET,2021-2031($MILLION)
FIGURE 32.JAPAN HUNTINGTON'S DISEASE TREATMENT MARKET,2021-2031($MILLION)
FIGURE 33.CHINA HUNTINGTON'S DISEASE TREATMENT MARKET,2021-2031($MILLION)
FIGURE 34.INDIA HUNTINGTON'S DISEASE TREATMENT MARKET,2021-2031($MILLION)
FIGURE 35.AUSTRALIA HUNTINGTON'S DISEASE TREATMENT MARKET,2021-2031($MILLION)
FIGURE 36.SOUTH KOREA HUNTINGTON'S DISEASE TREATMENT MARKET,2021-2031($MILLION)
FIGURE 37.REST OF ASIA-PACIFIC HUNTINGTON'S DISEASE TREATMENT MARKET,2021-2031($MILLION)
FIGURE 38.BRAZIL HUNTINGTON'S DISEASE TREATMENT MARKET,2021-2031($MILLION)
FIGURE 39.SAUDI ARABIA HUNTINGTON'S DISEASE TREATMENT MARKET,2021-2031($MILLION)
FIGURE 40.SOUTH AFRICA HUNTINGTON'S DISEASE TREATMENT MARKET,2021-2031($MILLION)
FIGURE 41.REST OF LAMEA HUNTINGTON'S DISEASE TREATMENT MARKET,2021-2031($MILLION)
FIGURE 42. TOP WINNING STRATEGIES, BY YEAR
FIGURE 43. TOP WINNING STRATEGIES, BY DEVELOPMENT
FIGURE 44. TOP WINNING STRATEGIES, BY COMPANY
FIGURE 45.PRODUCT MAPPING OF TOP 10 PLAYERS
FIGURE 46.COMPETITIVE DASHBOARD
FIGURE 47.COMPETITIVE HEATMAP OF TOP 10 KEY PLAYERS
FIGURE 48.PRILENIA THERAPEUTICS.: NET SALES ($MILLION)
FIGURE 49.SOM BIOTECH.: NET SALES ($MILLION)
FIGURE 50.BAUSCH HEALTH COMPANIES INC..: NET SALES ($MILLION)
FIGURE 51.TEVA PHARMACEUTICAL INDUSTRIES LTD..: NET SALES ($MILLION)
FIGURE 52.NOVARTIS AG.: NET SALES ($MILLION)
FIGURE 53.LUPIN.: NET SALES ($MILLION)
FIGURE 54.UNIQURE.: NET SALES ($MILLION)
FIGURE 55.HIKMA PHARMACEUTICALS PLC.: NET SALES ($MILLION)
FIGURE 56.ANNEXON BIOSCIENCES.: NET SALES ($MILLION)
FIGURE 57.DR. REDDY'S LABORATORIES LTD..: NET SALES ($MILLION)
FIGURE 58.NEUROCRINE BIOSCIENCES.: NET SALES ($MILLION)
FIGURE 59.PTC THERAPEUTICS.: NET SALES ($MILLION)
FIGURE 60.AOP HEALTH.: NET SALES ($MILLION)
FIGURE 61.MEDESIS PHARMA SA.: NET SALES ($MILLION)
FIGURE 62.MITOCHON PHARMACEUTICALS.: NET SALES ($MILLION)
FIGURE 63.SUN PHARMACEUTICALS INDUSTRIES LTD..: NET SALES ($MILLION)
FIGURE 64.VACCINEX, INC.: NET SALES ($MILLION)
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security